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ABSTRACT 
In the recent few decades, there was a growth in the field of radioactive medicinal agents called radiopharmaceuticals. Radiopharmaceuticals are 
consisting of radioactive materials called radioisotopes. Radiopharmaceuticals were recently used in both therapeutic and diagnostic purposes. More 
than 100 radioactive substances are used in nuclear medicine. According to the decay of radioactive substances, there are three types of radioactive 
decays, alpha particles, beta particles, and gamma radiations. Alpha particles consist of two protons and two neutrons with large mass and charge so it 
has no penetration power into the skin and has a destructive effect. Beta particles have less charge and less mass so, they can penetrate the tissue and 
have a less destructive effect than alpha particles and can be used in therapy. Gamma radiations have no mass or charge so they can penetrate the deep 
tissue of organs so used in diagnosis by imaging using a gamma camera. The radiopharmaceuticals were established in the diagnostic purpose and 
treatment of several diseases as thyroid gland cancer, hyperthyroidism, bone pain metastasis, kidney dysfunction, and myocardial and cerebral 
perfusion. The radioactive substance can also be used in the sterilization of thermo-labile substances as syringes, catheters, vitamins, hormones, and 
surgical dressing. The field of nuclear medicine has several advantages as localization of tumors, safe diagnosis, no accumulation of radiation, and high 
therapeutic efficacy. Nowadays, the branch of nuclear pharmacy is directed to introduce new radioactive pharmaceutical agents which will be important 
and effective in the treatment of cancer. The growth in the field of radiopharmaceuticals is important to help millions of patients suffering from tumors 
all over the world. The data of this review were collected by searching in Google Scholar and PubMed using the following keywords. 
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INTRODUCTION 
Radiopharmaceuticals are radioactive substances used in the fields 
of diagnosis and therapy [1]. In 1978, the board of pharmaceutical 
specialties introduced the nuclear pharmacy as a specialty in 
pharmacy, which concerns the safe and effective application of 
radioactive agents [2].  
There are more than 100 radioactive agents which used for 
therapeutic purpose as in localization of tumors, hyperthyroidism 
[3], toxic diffuse goiter [4], bone pain related to skeletal metastasis 
[5], cerebral perfusion [6]. Also, these radioactive drugs used in 
diagnosis as infection imaging and kidney dysfunction [7].  
There are a wide variety of radiopharmaceuticals having different 
mechanisms of targeting and different forms and also different route 
of administration may be given in simple salt form or attached to 
more complex molecules [8]. There are different rout of 
administration for radiopharmaceuticals, may be given orally 
parentally or installed into the eyes.  
Most of the radiopharmaceuticals (about 95%) are used for 
diagnostic purpose while the remaining are used in therapy [9]. 
Radiopharmaceuticals are different than the traditional drugs in 
being there is no pharmacological effect [10].  
The radiopharmaceuticals provide a non-invasive mechanism for 
targeting the therapeutic radiations with low side effects [11]. Also, 
in case of diagnosis, radioactive drugs represent non-invasive 
imaging agents which give information about the structure and 
function of diseased organs or tissue [12]. 
The aim of this review is to introduce valuable information about the 
safe and effective use of radiopharmaceuticals in the fields of 
diagnosis and therapy.  
Radiopharmaceuticals 
The radiopharmaceuticals are radioactive substances which 
disintegrate instantaneously by emitting radiations [13]. The 
radioactive nuclides are like normal nuclides having the same number 
of protons with different numbers of neutrons. The emitted radiation 
may be in the form of alpha, beta, and gamma radiation [14]. The dose 
of radiopharmaceuticals is dispensed to the patient in the form of 
Curie, which equals to 3.7×1010 decomposition per second [15].  
The radioactive substances are different in the half-life, which defined 
as the time needed to the disintegration of active substances to half the 
initial concentration [16]. As represented in table (1), an example of 
the most important radiopharmaceuticals and their half-life’s. 
Radiopharmaceuticals can be divided into four categories 
• Radiopharmaceutical preparation  
It is a preparation which contains radionuclide and ready to use by 
humans. The Presence of the radionuclide is very important, making 
the preparation useful in the diagnosis or therapy [28]. 
• Radionuclide generator 
It is the system that allows separation of a daughter radionuclide 
(short half-life) from a parent radionuclide (long half-life) by elution 
or by other means to allow the use of later in the production of a 
radiopharmaceutical preparation [29].  
• Radiopharmaceutical precursor  
A radionuclide produced for the radiolabelling process with a 
resultant radiopharmaceutical preparation [30]. 
• Kit for radiopharmaceutical preparation  
The kits intended for preparation of the radiopharmaceutical 
preparation are usually in the form of sterilized and validated vial 
containing the non-radionuclide components. The radionuclide is 
added to the vial just before use. After the addition of the 
appropriate radionuclide, additional steps may be needed as boiling, 
filtration, and buffering. The prepared radiopharmaceuticals must 
be used within 12 h after preparation [31]. 
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Table 1: Different types of radionuclide and their halve life’s 
Radionuclide Half-life References 
99mTC (Technetium-99m) 6.02 hour [17] 
131I (Iodine-131) 8 d [18] 
18F (Fluorine-18) 110 min [19] 
123I (Iodine-123) 13.27 h [20] 
67Ga (Gallium-67) 3.26 d [21] 
133Xe (Xenon-133) 5.24 d [22] 
201Tl (Thallium-201) 3.04 d [23] 
89Sr (Strontium-89) 50.53 d [24] 
125I (Iodine-125) 59.41 d [25] 
57 Co (Cobalt-57) 271.79 d [26] 
153Sm (Samarium-153) 1.93 d [27] 
  
Radionuclide production  
The radionuclides which intended for use in the radiopharmaceutical 
preparation can be prepared by one of the following methods. 
• Nuclear fission  
Nuclides with a high atomic number are characterized by being 
fissionable. The most common reaction is the fission of Uranium-235 
by neutrons within the nuclear reactor. Anther examples of 
radionuclides prepared by this method are Iodine-131and Xenon-
133. The radionuclides prepared by this method must be carefully 
controlled to avoid radiation impurities [32].  
• Charged particle bombardment  
In this method, the cyclotrons are used to produce the radionuclide 
by bombarding the non-radionuclide with charged particles [29].  
• Neutron bombardment  
In this method, the radionuclides are prepared in the nuclear reactor 
by bombarding the non-radionuclide by neutrons [33]. Didi et al. 
studied the feasibility of the production of iodin-131 using dioxide of 
tellurium-130 under neutron activation [34].  
• Radionuclide generator systems  
This method is used for preparing the radionuclides with short half-
life by separating the daughter radionuclide (short half-life) from 
the parent one (long half-life) by physical or chemical means using 
radionuclide generator system [29].  
Labeling and packaging of radiopharmaceuticals  
The label on the package should have the following information [35]:  
• The name of the product and also the name of the added 
radionuclide. 
• The code of the product. 
• The name of the manufacturing company.  
• The batch number. 
• For liquid preparations, the total volume in the vial, and the 
total concentration of radionuclide within the vial or the 
concentration per milliliter at the date and time of the 
manufacturing.  
• For solid preparations (lyophilized powder), the total amount 
of radionuclide at the date and time of the manufacturing.  
• For capsules, the total number of capsules in the package and 
also the amount of radionuclide in each capsule. 
• All ingredients should be mentioned in the label. 
• The route of administration and the expiration date. 
• Specific storage conditions.  
Packaging  
The packing and labeling materials should be suitable for the 
condition of the product [36]. 
The package leaflets  
Package leaflets of the kits or the product should include:  
• The name and the use of the radioactive product.  
• The name of all ingredients in the product. 
• The name of the manufacturer of the kits and the address. 
• The method of preparation of radiopharmaceutical from the 
kits and the Shelf-life of the prepared radiopharmaceutical. 
• The route of administration, the pharmacological and 
toxicological effect of the prepared radiopharmaceutical and also the 
route of elimination from the body. 
• The dose of radioactive substance from the prepared 
radiopharmaceutical.  
• The Precautions which should be considered by the patient and 
the nuclear pharmacist during administration and the preparation of 
the product.  
• The precautions which should be taken in consideration for the 
disposal of the container and its unused contents. 
• The recommended dose of the prepared radiopharmaceuticals. 
Storage of radiopharmaceuticals 
The international standard guidelines for the storage of radioactive 
substances should be strictly applied [35]. The prepared 
radiopharmaceuticals should be stored in a well-closed container in 
a sufficiently shielded place to protect personnel from exposure to 
radiation.  
Radioactivity  
As shown in fig. (1), the different types of radioactive decays, which 
include alpha, beta, and gamma. The difference between the 
different types of radioactive decays is represented in table (2). 
 
 
Fig. 1: Types of radioactivity: alpha, beta, and gamma decay [37] 
 
 Alpha particle 
Alpha particles as helium nucleus consisting of two protons and two 
neutrons, which means that when the radionuclide decay and emit 
alpha particle, its atomic number will be decreased by 2 and also the 
atomic mass decreased by 4. The alpha particles are heavy with high 
mass and slow so, they have low penetration power, which allows 
them to be stopped by a sheet of paper [38]. Due to the high mass of 
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the alpha particles, they can’t penetrate the outer layer of the skin 
when the body exposed to it and not cause a hazard's effect. While 
when the alpha particle emitters are inhaled, ingested or injected, 
the alpha particles cause a serious hazard effect on the internal 
organs due to the high charge of the alpha particles. 
 Beta particle 
The beta particles resemble the electron in the mass and charge, 
which indicates that they have a very small mass in comparison to 
protons or neutrons. Beta particles may be of negative charge 
(negatron) or positive charge (positron). Due to the low mass of the 
beta particles, they have penetration power higher than the alpha 
particle which allows them to penetrate the sheet of paper but 
stopped by an aluminum sheet. Being charged, the beta particle has 
a destructive effect on the organs but less than alpha particles so, 
they can be used in therapy especially for the destruction of the 
tumor tissue [39]. 
 Gamma radiation 
The gamma radiations are emitted from the radioactive nuclide in the 
form of photons, not particles that means that they haven’t a mass or 
charge. The radionuclides are decayed in the form of gamma 
radiations, the process not accompanied by any change in the atomic 
number or the atomic mass. Being radiation, the gamma rays have no 
mass so have high penetration power more the beta particles. Due to 
the absence of the charge, the gamma radiations have no destructive 
effect so, can be used for diagnosis. Technetium-99m is an example of 
a radionuclide which decayed in form of gamma radiation [39]. 
 
Table 2: Different types of radioactive decays of radiopharmaceuticals 
Types of decay Alpha (α) Beta (β) Gamma (γ) Reference 
Structure and origin Like helium nucleus emitted from the 
radionuclide  
Like electron emitted from the 
radionuclide 
Like waves emitted 
from the radionuclide 
[40] 
Charge  α2+ β− or β+, Zero [39] 
Mass  4 1/1836 Zero [39] 
Ionization degree in 
the human body 
Highly ionized so cause a destructive 
effect and can’t be used in nuclear 
medicine 
Less than alpha particle can’t be 
used for diagnosis but used for 
therapy 
No ionization so can be 
used in imaging 
[40] 
Suitability for nuclear 
imaging 
Not suitable Not suitable Highly suitable [39] 
 
The nuclear medicine  
Radiopharmaceuticals are pharmaceutical preparations that contain 
radioactive substances and radiolabel substances to be used either 
in diagnosis or therapy. 
The Society of Nuclear Medicine, state that 20 million nuclear 
medicine procedures are carried out in the United States every year. 
These procedures are done using the prepared 
radiopharmaceuticals and the imaging equipment for the diagnosis 
of a different disease or in treatment targets [41]. 
Advantages and disadvantages of nuclear medicine 
Advantages of nuclear medicine 
As shown in fig. (2), nuclear medicine has several advantages 
 
 
Fig. 2: The advantages of nuclear medicine 
 
• Providing information about the function and anatomy of the body 
The tests of nuclear medicine give complete information about the 
functions and anatomy of body organs. It represents a useful tool for 
the physician to determine the case of the patient and the best 
treatment. From the scan of the body, it is easy to decide on the 
tumor is malignant or benign, the physician can determine if surgery 
is required or not, and it is easily discovering the presence of disease 
before the appearance of the symptoms [42]. 
• Determination of the cancer status 
Nuclear medicine is a useful tool for determining the status of the 
tumor. The physician can know if the tumor is metastasized or 
returned after size reduction [43].  
• Nuclear medicine is important in bone metastasis 
The bone pain source and the presence of bone cancer can be 
detected by nuclear medicine. Also, for an elderly patient, nuclear 
medicine serves as a tool for detecting the hidden features which 
resulted from osteoporosis [44, 45]. 
• Nuclear medicine is important in heart disease (cardiology) 
Nuclear medicine is used by the cardiologist to recognize the causes 
of certain symptoms like the breath shortage and chest pain. Also, 
the nuclear medicine used for diagnosis of coronary artery disease 
caused by high cholesterol level, which causes the block of the blood 
and oxygen supply to the heart [46]. 
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• Nuclear medicine minimizes the amount of radiation  
The tissue and organ damage for patients can be done due to too 
much exposure to the radiation. While in the use of nuclear 
medicine, the amount of radiation is minimized to be as the usual x-
ray [29].  
• Nuclear medicine helps in accurate, painless, and safe 
diagnosis of several diseases 
Nuclear medicine represents as accurate, non-invasive, safe, 
effective tool to manage the complex diagnosis as in case of patients 
suffering from many concurrent diseases. It gives a clear image and 
important information that can’t be given with other diagnostic 
tests. It is important in the diagnosis of thyroid disease, bone Bain, 
and blood imbalance [29]. 
• Nuclear medicine is important in therapy 
Some of the radioactive agents have therapeutic efficacy so they 
can be used by the physician in the treatment plan. They are 
used for the treatment of cases that can’t be controlled by 
conventional drugs as in case of bone pain. Nuclear medicine 
also is useful in the case of thyroid cancer and hyperthyroidism 
[47].  
• The radioactivity of radiopharmaceutical agents passes 
through the patient’s body  
After administration of the accurate dose of the 
radiopharmaceuticals, the gamma rays are emitted to give the 
therapeutic effect and the excess is passed through the body via 
stool and urine, so no accumulation of radiation inside the body due 
to radioactive decay [48].  
The disadvantages of nuclear medicine 
Nuclear medicine has several disadvantages as shown by a fig. (3) 
 
 
Fig. 3: The disadvantages of nuclear medicine 
 
• Nuclear medicine is not recommended for the pregnant and 
breastfeeding woman 
The unborn babies have great sensitivity to the radiation of 
radiopharmaceutical drugs than children and adults [49]. 
• Nuclear medicine may cause an allergic reaction in some cases 
The allergic reaction accompanied to nuclear medicine is rare. It 
may occur for 1 every 400000 cases. The patient should speak with 
the physician about his history before stating nuclear medication, 
especially if the patient suffered from any medication allergy or have 
anaphylaxis shock in the past. The most popular side effects of 
radiotherapy are headache, dizziness, low blood pressure, and 
abnormal heart rate [50]. 
• Specific consideration should be followed before starting the 
nuclear medicine in some cases 
A special construction should be followed by the patient before 
starting a nuclear medicine such as in the case of thyroid, heart, and 
gastrointestinal tract scan. In the thyroid scan, the patient should 
stop any medication for about 2-4 w before the nuclear medicine. In 
the case of heart examination, the patient should fast for at least 4 h 
before nuclear medicine. In the case of the gastrointestinal system, 
the patient should undergo certain required premedication tests and 
be fasted for about 4 h before starting the nuclear medication [51].  
• The high cost of nuclear medication  
Most of the patients can’t tolerate the therapy cost, so these patients 
resort to cover the cost of treatment by medical insurance or to be 
taking a grant from the government. The high cost of nuclear medicine 
is due to the medical instruments used in this purpose [52]. 
• Side effects related to nuclear medicine 
The exposure of the patient to the nuclear medication may lead to 
the teeth failing, dental braces and distortion around the mouth area 
[53].  
• Nuclear medicine may consume a long time 
When the patient receives a radiopharmaceutical agent, the imaging 
may be done after about 30-60 min, several hours, or several days to 
obtain good results. The time varies according to the decay time of 
the radiopharmaceutical agent to emit the radiations [54]. 
Application of radiopharmaceuticals 
Radiopharmaceuticals have several applications as shown by a fig. (4). 
 
 
Fig. 4: The applications of radiopharmaceuticals 
 
A-The therapeutic application of radiopharmaceuticals 
The radiopharmaceutical preparations intended for therapeutic 
purposes are designed to deliver the radiolabeled molecules to 
specific diseased sites inside the body to allow the emission of 
charged beta particles in the target site to give therapeutic 
responses as in the case of tumors. As represented in table (3), some 
radiopharmaceuticals with their therapeutic applications.  
The ideal properties of therapeutic radiopharmaceuticals are [9]: 
• High uptake at a specific site  
• Less activity in the blood 
• No retention in any other tissue or organ 
• Excretion through the renal pathway 
The therapeutic radiopharmaceuticals are used in different fields as 
in cardiology for myocardial perfusion, oncology for tumors, and 
neurology for cerebral perfusion. 
Application of radiopharmaceuticals in the treatment of 
hyperthyroidism and thyroid cancer 
Hyperthyroidism is the elevated production of thyroid hormone 
from the thyroid gland, which resulted in a clinical case called 
thyrotoxicosis [55]. 
Oral administration of Iodine-131 has been a frequently accepted 
route for the treatment of malignant and benign thyroid disorder 
and hyperthyroidism [56]. 
Iodine-131 is a radioisotope with a half-life of 8 d. It decays in the 
form of gamma rays and beta particles [57]. The therapeutic effect 
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of Iodine-131 depends on the ability of iodine to concentrate in the 
thyroid gland [58]. 
The radiolabeled Iodine-131 can be administered as first-line 
treatment if the hyperthyroidism returns or not controlled after 
treatment with an anti-thyroid drug or after thyroid surgery [59].  
The radiolabeled Iodine-131 is selectively accumulated in the tissue 
of thyroid gland and decays by emission of alpha particle, which 
destroys the tumor tissue in case of thyroid cancer. 
Radiolabeled Iodine-131 may be administered in oral dosage form 
(liquid or capsules) or parentally (intravenous injection) for patients 
having difficulty in swallowing or vomiting. 
Application of radiopharmaceuticals in the treatment of bone 
metastasis 
Bone metastasis is the most common type of pain in cancer patients. 
It reduces patient quality of life and linked with many complications, 
such as hypercalcemia, bone fractures, spinal cord compression [5]. 
Treatment is mainly palliative by using analgesic drugs, anti-
inflammatory drugs, radiotherapy and surgery [60]. 
Various radionuclides are used to provide analgesic treatment of 
bone metastases, including samarium-153 (Sm-153), phosphorus-32 
(P-32) and strontium-89 (Sr-89) [10]. 
Samarium-153 is a radionuclide with 1.9 d half-life which can be 
used for diagnosis and treatment of bone metastasis due to the 
emission of both beta particle and gamma radiation [10]. Samarium-
153 has the ability to target the bone tumor, it goes to the source of 
cancer bone pain and emits the beta particles resulting in pain relief. 
In the majority of patients, pain relief occurs within the first week of 
therapy.  
Phosphorus-32 used to suppress hyper proliferative cells. It emits 
beta particles with a physical half-life is 14.3 d. It decays in the form 
of beta particles with a maximum energy of 1.71 MeV allow it to be 
useful in case of bone metastasis [61]. 
Strontium-89 chloride is administered intravenously, it deacys and 
emits beta particles. The physical half-life of Strontium-89 is 51 d. It 
has the ability to accumulate metastatic bone lesions in higher 
concentrations than in healthy normal bone. After intrsvenous 
injection, the Strontium-89 acts as calcium it selectively cleared from 
the blood and localized in the bone minerals [62]. 
  
Table 3: The therapeutic application of radionuclides 
Radionuclide The therapeutic use Reference 
Iodine-131, Ytrium-90 Used for treatment of non-Hodgkins lymphoma [63, 64] 
Americum-241, Californium-252  
Cobalt-60, Gold-194 
Used for treatment of cancers and tumors [65, 66] 
Holmium-66 Used for treatment of liver cancers [10] 
Iodine-131  Used as antineoplastic, and for Grave’ disease (hyperthyroidism and differentiated 
thyroid cancer. 
[67] 
Rhenium-186 Used for relief the pain associated with bone metastasis [68] 
Ytrium-90 Used as cancer brachytherapy [69] 
Samarium-153, Strontium-89  
Phosphorus-32 
Palliative treatment of bone metastasis [70–72] 
Erbium-169, Ytrrium-90 Relief of arthritis pain [73] 
Samarium-153 Pain relief in bone cancer, prostate and breast cancer [70] 
Strontium-89 Reduces pain in prostate and bone cancer [74] 
 
B-The diagnostic application of radiopharmaceuticals 
The bodies' organs differ in their function. Throughout the study, the 
physicians identified the chemical substances which can be uptaken 
and absorbed by each organ. For example, the thyroid gland 
selectively uptake Iodine, the brain uptake the glucose, and the bones 
uptake the calcium. This idea is used in the case of 
radiopharmaceuticals, where the radioisotope when entering the body 
is selectively uptaken by certain organs. The ideal diagnostic 
radionuclide is that with short half-life and decay by emission of 
gamma radiation. Technetium-99 m is considered the ideal diagnostic 
radionuclide as it has a short half-life (6 h), decay by emission of 
gamma radiation only, and efficiently detected by gamma camera [75].  
As represented in table (4), diagnostic radiopharmaceuticals can be 
used to detect different diseases and image different organs. 
Curtis et al. used radioactive fluorine-18 for early diagnosis of 
Alzheimer's disease [76]. Vente et al. used radioactive Holmium-166 
to detect and diagnose liver cancer [77]. Maxon et al. used 
Radioiodene-131 in the diagnosis of metastatic thyroid cancer 
[78]. Mandel, et al. used iodine-123 in the scanning of thyroid 
remnants in patients with differentiated thyroid cancer [79]. El-
motaleb et al. prepared radioiodopropranol using iodin-125 for lung 
perfusion scan [80]. Visakh et al. estimated the amount of radiation 
that entered the thyroid region during a computed tomography (CT) 
brain scan [81]. 
 
Table 4: The diagnostic application of radionuclides 
Radionuclide  The diagnostic use  Reference 
Technetium-99 m Used in diagnosing of cardiac amyloidosis [82] 
Chromium-51 Used in diagnosis of pernicious anemia [83] 
Fluorine-18 Used in positron emission tomography to assess alternations in glucose metabolism in brain and cancer [76] 
Holmium-166  Used in the diagnosis of liver cancer [77] 
Iodine-125  Used in diagnosis and evaluation of the glomerular filtration rate of kidneys [84] 
Gallium-67  Used in tumors imaging  [85] 
Potassium-42  Used in determination of exchangeable potassium in coronary blood flow [86] 
Rubidium-86 Used in determination of myocardial blood flow [87] 
Iodine-131  Used in studying the function of the thyroid gland  [88] 
Selenium-75  Used to study the production of digestive enzymes [89] 
Sodium-24  Used to study sodium exchange [90] 
Xenon-133  Used to study the pulmonary ventilation [91] 
Thallium-201  Used to diagnose coronary artery disease, death of heart muscle, and the location of lymphoma (low grade)  [92] 
Strontium-92 Used in imaging of neuroendocrine tumors [10] 
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C-Application of radioactive substances in sterilization 
The thermo-labile substances are sterilized by radiation. The 
radioisotopes are used for this purpose. The thermo-sensitive 
substances include hormones, vitamins, antibiotics, surgical 
dressings, and disposable syringes. Cobalt-60 is an example of 
radioisotopes that decay by gamma radiation and used for 
sterilization of the thermo-labile substances [93].  
CONCLUSION 
The authors concluded that there are a lot of radioactive substances 
that have a great effect on diagnosis and therapy. Nowadays, the 
branch of nuclear pharmacy is directed to introduce new radioactive 
pharmaceutical agents which will be important and effective in the 
treatment of cancer. The growth in the field of radiopharmaceuticals 
is important to help millions of patients suffering from tumors all 
over the world. 
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